FGFR2 translocation is a common genetic lesion in iCCA and increasingly used as a biomarker to predict the sensitivity to FGFR kinase inhibitors in iCCA-targeted therapy. The gene discussed is FGFR2; the disease is infantile convulsions and choreoathetosis.